MEDI5395
AXP000118.2 · Oncolytic virus
- Platform
- Newcastle disease virus (LaSota-derived, recombinant)
- Originator
- MedImmune
- Sponsor
- AstraZeneca
Names
Virus
- Role
- Oncolytic
- Family
- Paramyxoviridae
- Virus
- Newcastle disease virus (NCBI Taxonomy 2560319)
- Strain
- LaSota-derived recombinant
- Replication
- replicating
- Modifications
- recombinant NDV backbone armed with GM-CSF
- Transgenes
- CSF2
- Route
- intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C165457
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03889275 | A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors | Completed | Phase 1 | 2019-10-24 | 2021-11-19 | 39 | Advanced Solid Tumors |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39551600 | Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. | Journal for immunotherapy of cancer | 2024 | cited by trial NCT03889275 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 34224361 | Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. | Molecular cancer therapeutics | 2021 | name in abstract: MEDI5395 |
| PMID 32088771 | Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. | Cancer immunology, immunotherapy : CII | 2020 | name in abstract: MEDI5395 |
Notes
Recombinant NDV armed with GM-CSF (recNDV(GM-CSF)). Phase 1 with durvalumab completed 2022; no follow-on trial found, so presumed discontinued. Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
MEDI5395 (AXP000118.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000118.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.